Valeant: net loss slashed in Q2.

(CercleFinance.com) - There's some good news for Valeant, which has divided its net loss per share by eight in Q2.


Indeed, the group's loss per share has fallen from 88 cents to 11 cents over the past year.

However, the group's revenues have slipped from 2.42 billion dollars in April-June 2016, to 2.233 billion dollars this year.

The Canadian pharmaceutical group is also less optimistic about its FY revenues. These are expected to reach between 8.7 billion dollars and 8.9 billion dollars, compared with a previous forecast range of 8.9 billion dollars to 9.1 billion dollars.


Copyright (c) 2017 CercleFinance.com. All rights reserved.